A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Dilanubicel (Primary)
- Indications Acute myeloid leukaemia
- Focus Pharmacodynamics
- Acronyms LAUNCH
- Sponsors Nohla Therapeutics
- 02 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 13 Feb 2019 Planned End Date changed from 1 May 2019 to 1 Mar 2019.
- 13 Feb 2019 Planned primary completion date changed from 1 May 2019 to 1 Mar 2019.